Clinical role of bisphosphonates in the treatment of prostate cancer bone metastases

    Research output: Contribution to journalReview articlepeer-review

    Abstract

    Intravenous bisphosphonates are the current standard of care for patients with multiple myeloma or breast cancer and bone metastases. However, until recently, bisphosphonates had not demonstrated any significant clinical benefit in patients with prostate cancer and bone metastases. Zoledronic acid is the only bisphosphonate to significantly reduce skeletal complications and durably palliate bone pain in patients with advanced prostate cancer. Recently, the use of zoledronic acid for prostate cancer has been approved by the government. In this article, the mechanism and clinical role of zoledronic acid are reviewed.

    Original languageEnglish
    Pages (from-to)569-574
    Number of pages6
    JournalNishinihon Journal of Urology
    Volume68
    Issue number12
    Publication statusPublished - Dec 2006

    Keywords

    • Bisphosphonates
    • Prostate cancer
    • SRE (skeletal-related events)
    • Zoledronic acid

    ASJC Scopus subject areas

    • Urology

    Fingerprint

    Dive into the research topics of 'Clinical role of bisphosphonates in the treatment of prostate cancer bone metastases'. Together they form a unique fingerprint.

    Cite this